AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical ...
After Apellis Pharmaceuticals and partner Sobi ran into a clinical setback and ended the open-label extension arm of a study testing their amyotrophic lateral sclerosis (ALS) candidate, the companies ...
Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating ...
The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in ...
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical ...
NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...
Bolstering a Resurgence in Novel Approaches to Target Underlying Pathology, Address Disease Heterogeneity and Restore Hope in a More Transformative Wave of ALS and FTD Therapies. Uniting ALS Biotech, ...
Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...
REDLANDS, Calif.--(BUSINESS WIRE)--The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, ...
Athira Pharma, Inc. has announced favorable results from a Phase 1 clinical trial of its drug candidate ATH-1105, which targets neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). The ...
Funding aims to bring high quality ALS care closer to home and more accessible for people living with ALS nationwide "Thanks to this transformational gift, we are able to support clinical programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results